Efgartigimod safety study for pregnancy and breastfeeding
Treatments studied
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This study is for women who have taken efgartigimod (a medicine for certain autoimmune conditions) right before or during pregnancy, or while breastfeeding. Researchers will monitor moms, fetuses, and babies to check for side effects and ensure safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were exposed to efgartigimod within 25 days before becoming pregnant or anytime during pregnancy.
- You were exposed to efgartigimod while breastfeeding.
- You are willing to provide consent (or for minors, have a parent or guardian provide consent).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how safe efgartigimod is for people with generalized myasthenia gravis (gMG), whether they are taking the drug now, will start it soon, or are not taking it at all.
This study tests whether continuing efgartigimod after a myasthenia gravis crisis helps keep symptoms under control and prevent future flare-ups. It is for people who have already responded to one round of this treatment.
This trial tests whether a follow-up treatment with ublituximab (given as an infusion) can help myasthenia gravis patients who first received efgartigimod. The goal is to see if it provides lasting control of MG symptoms.
This study tests a new combination treatment for generalized myasthenia gravis. It combines two medications to help reduce muscle weakness and improve your daily life.
This study tests an investigational drug called efgartigimod for children and teens with generalized myasthenia gravis. It may help those who haven't responded well enough to standard treatments.
This study tests the long-term safety and effectiveness of a subcutaneous (under-the-skin) version of efgartigimod for adults with active idiopathic inflammatory myopathy. It is for people who have already completed an earlier study of this medicine.
Hear when a new Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.